Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Vo, Kieuhoa; Matthay, Katherine; DuBois, Steven
• Is Part Of: Clinical sarcoma research. Volume 6:Issue 1(2016)
• Page Start: 1
• Page End: 11
• Publication Date: 2016-12
• Subjects: Sarcoma -- Antiangiogenesis -- Combination drug therapy -- Combination chemotherapy; Sarcoma -- Periodicals; 616.994
• DOI: 10.1186/s13569-016-0049-z
• Languages: English
• ISSNs: 2045-3329

Abstract

Abstract Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients with these tumors. In the current review, the authors summarize the available evidence and possible mechanisms supporting this approach.